HSA
SGMO

Hussman Strategic Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Hussman Strategic Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,000
Closed -$431K – 349
2021
Q2 		$431K Hold
36,000
– – 0.09% 277
2021
Q1 		$451K Buy
+36,000
New +$485K 0.09% 267

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hussman Strategic Advisors's SGMO Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 36,000 shares — an estimated $431K sold.

Hussman Strategic Advisors first reported a position in SGMO in Q1 2021 and held it in 2 quarters. The position peaked at $451K in Q1 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

  • Hussman Strategic Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 36,000 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $431K.
  • Hussman Strategic Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 2 quarters.
  • Hussman Strategic Advisors's SANGAMO THERAPEUTICS INC position peaked at $451K in Q1 2021.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.